tepotinib: Clinical Trials

17 trials of tepotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 17 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 117Completed 11, Active not recruiting 2, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 26Completed 3, Active not recruiting 1, Terminated 1, Unknown 1

Follow tepotinib: new trials by email Literature Review of tepotinib trials Research Report on tepotinib

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Tepotinib, Ivonescimab - Non-Small Cell Lung Cancer
Phase 1RecruitingMemorial Sloan Kettering Cancer Center162026-05-272026-09-16
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
Amivantamab, Tepotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center32024-06-182026-09-11
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Tepotinib, Pembrolizumab - Advanced Cancer, Non Small Cell Lung Cancer
Phase 1Active not recruitingInstitute of Cancer Research, United Kingdom192023-05-032026-04-24
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
tepotinib, tepotinib plus osimertinib - Brain Tumor
Phase 1WithdrawnM.D. Anderson Cancer Center2023-02-272024-04-17
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Tepotinib - Advanced Non-Small Cell Lung Cancer With MET Mutations
Phase 1 / Phase 2TerminatedCriterium, Inc.22022-05-252023-10-18
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Tepotinib plus paclitaxel - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 1 / Phase 2UnknownHallym University Medical Center422022-03-012022-07-05
Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants
Tepotinib (HydroChloride hydrate), Itraconazole - Healthy
Phase 1CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany182022-01-212024-02-20
Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants
Tepotinib, Carbamazepine - Healthy
Phase 1CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany182021-12-152024-03-08
Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Tepotinib 100 mg, Tepotinib 250 mg - Healthy
Phase 1CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany182019-10-172023-11-08
Effect of Tepotinib on PK of CYP3A Substrate Midazolam
Midazolam, Tepotinib - Healthy
Phase 1CompletedMerck KGaA, Darmstadt, Germany122018-08-202023-07-28
Tepotinib Hepatic Impairment Trial
Tepotinib - Hepatic Impairment
Phase 1CompletedEMD Serono Research & Development Institute, Inc.182018-06-132024-08-12
Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate
Dabigatran Etexilate, Tepotinib - Healthy
Phase 1CompletedMerck KGaA, Darmstadt, Germany202018-05-172023-08-07
Effect of a Proton Pump Inhibitor on the PK of Tepotinib
Tepotinib, Omeprazole - Healthy
Phase 1CompletedMerck KGaA, Darmstadt, Germany122018-05-142023-07-28
c-Met Second-Line Hepatocellular Carcinoma
Tepotinib - Carcinoma, Hepatocellular
Phase 1 / Phase 2CompletedMerck KGaA, Darmstadt, Germany662014-05-182022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg - Carcinoma, Hepatocellular
Phase 1 / Phase 2CompletedMerck KGaA, Darmstadt, Germany1172014-01-062022-08-24
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Tepotinib, Gefitinib, Pemetrexed - Non-small Cell Lung Cancer
Phase 1 / Phase 2CompletedMerck KGaA, Darmstadt, Germany882013-12-232022-11-08
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
MSC2156119J - Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Phase 1CompletedEMD Serono1492009-11-302022-08-24

Conditions studied

Carcinoma, Non-Small-Cell Lung (7)  ·  Carcinoma, Hepatocellular (2)  ·  Brain Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Stomach Neoplasms (1)

Sponsors

Merck KGaA, Darmstadt, Germany (6)  ·  Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (3)  ·  M.D. Anderson Cancer Center (2)  ·  Criterium, Inc. (1)  ·  EMD Serono (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  Hallym University Medical Center (1)  ·  Institute of Cancer Research, United Kingdom (1)  ·  Memorial Sloan Kettering Cancer Center (1)

Countries

Germany (7)  ·  United States (5)  ·  South Korea (3)  ·  China (2)  ·  Taiwan (2)  ·  Italy (1)  ·  Malaysia (1)  ·  Singapore (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Anna Minchom, MD (1)  ·  Barbara O'Brien, MD (1)  ·  Dae Young Zang, Dr (1)  ·  David R Camidge, MD, PhD (1)  ·  Paul Paik, MD (1)  ·  Tejas Patil, MD (1)  ·  Xiuning Le, MD,PHD (1)

Results publications

PMID 35771259, PMID 37415001, PMID 40679917, PMID 31822497, PMID 32479794, PMID 33824476, PMID 33972742, PMID 36101520, PMID 40880848

NIH funding

2017 (3), 2016 (1), 2019 (1)